10x Genomics (TXG) Competitors

10x Genomics (NASDAQ:TXG) and Sensata Technologies (NYSE:ST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.

Does the media favor TXG or ST?

In the previous week, 10x Genomics and 10x Genomics both had 17 articles in the media. Sensata Technologies' average media sentiment score of 1.32 beat 10x Genomics' score of 0.75 indicating that Sensata Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensata Technologies	12 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor TXG or ST?

Sensata Technologies received 385 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 61.56% of users gave Sensata Technologies an outperform vote while only 50.39% of users gave 10x Genomics an outperform vote.

Company	Underperform	Outperform
10x Genomics	Outperform Votes 65 50.39%	Underperform Votes 64 49.61%
Sensata Technologies	Outperform Votes 450 61.56%	Underperform Votes 281 38.44%

Which has stronger valuation & earnings, TXG or ST?

Sensata Technologies has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Sensata Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$624.66M	1.78	-$182.63M	-$1.30	-6.98
Sensata Technologies	$3.84B	1.02	$128.48M	$0.81	33.11

Which has more risk and volatility, TXG or ST?

10x Genomics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Sensata Technologies has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.

Is TXG or ST more profitable?

Sensata Technologies has a net margin of 3.27% compared to 10x Genomics' net margin of -29.90%. Sensata Technologies' return on equity of 17.54% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-29.90%	-25.40%	-19.69%
Sensata Technologies	3.27%	17.54%	6.86%

Do analysts rate TXG or ST?

10x Genomics presently has a consensus target price of $15.81, indicating a potential upside of 74.09%. Sensata Technologies has a consensus target price of $34.08, indicating a potential upside of 27.08%. Given 10x Genomics' stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Sensata Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Sensata Technologies	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do institutionals and insiders hold more shares of TXG or ST?

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.4% of Sensata Technologies shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 0.9% of Sensata Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sensata Technologies beats 10x Genomics on 11 of the 17 factors compared between the two stocks.